Inherited skin blistering disorders
Rheacell GmbH & Co. KG focuses on clinical research in epidermolysis bullosa, with attention to both recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa. The sponsor’s work in this area is centered on severe skin fragility, chronic wound burden, and the need for therapies that support wound improvement in affected patients.
- Recessive dystrophic epidermolysis bullosa
- Junctional epidermolysis bullosa
- Wound healing
Clinical activity in this field includes both adult and very young patients, reflecting interest in difficult-to-treat inherited skin disease across age groups.
Chronic venous ulcer care
The company also conducts research in chronic venous ulcers, including therapy-resistant and long-term non-healing lesions. This therapeutic area highlights a strong focus on persistent lower-limb wound disease, where closure of chronic ulcers remains a central clinical goal.
- Chronic venous ulcers
- Non-healing venous leg ulcers
- Ulcer closure
Its studies in this domain address patients with wounds that have not responded adequately to standard care, underscoring interest in advanced wound management.
Cell-based and regenerative therapies
Rheacell’s trial portfolio includes investigations involving stem cell and mesenchymal cell therapies for dermatologic and wound-related conditions. This indicates an emphasis on regenerative approaches aimed at restoring tissue integrity and supporting repair in chronic skin injury.
- Stem cell therapy
- Mesenchymal stromal cells
- Regenerative wound treatment
These activities connect cellular medicine with unmet needs in inherited blistering disease and chronic ulceration.
